Eli Lilly plucks a new commercial chief from Bristol Myers in management shuffle as HR chief retires
Eli Lilly has found a new chief commercial officer from among the ranks at Bristol Myers Squibb, as it says farewell to its longtime head of human resources Stephen Fry.
Fry announced on Thursday his plans to retire after more than 35 years with Lilly. He’ll vacate his seat as SVP of human resources and diversity at the end of the year, and current Loxo CCO Eric Dozier is slated to take his place. As a result, BMS’ Winselow Tucker is joining the team as Loxo CCO at the end of the month.
Tucker is leaving his post as intercontinental SVP at BMS, a job he’s held for only about eight months. Before that, he was the SVP and general manager of the hematology business, where, among other accomplishments, he was one of the leaders behind the pharma giant’s $300 million commitment to combat racial disparities.
“What I’m really excited about is that this is a tangible view,” he told Endpoints News back in 2020, “that we’re not just looking externally, we’re also looking internally as well to figure out how can we support the right equity across both our internal organizations and in the communities of patients that we serve.”
Tucker has been vocal about addressing racial disparities within healthcare and was also involved in BMS’ Standing in the Gaap program designed to close gaps in the diagnosis, care and survival rates of African Americans with multiple myeloma.
Our own Winselow Tucker shared his perspective on inclusive innovation and ways to ensure equitable access to healthcare for underserved populations at @FortuneMagazine @BStormHealth. #FortuneHealth #HealthEquity pic.twitter.com/CE0H6fIn5f
— Bristol Myers Squibb (@bmsnews) May 11, 2022
“I grew up in New York City, a city of contrasts. I saw this first-hand when it came to information, education, and opportunities. That awareness shaped who I am today and how I see and understand the world. I know that access to healthcare and medicines can change someone’s life,” he wrote in a LinkedIn post marking his 100th day as BMS’ intercontinental SVP.
Tucker added that he was ready to transition from “the initial period of listening and learning to lean into our goals with full force.”
“Winselow brings deep expertise in both oncology and hematology that will support the continued growth of our existing commercial portfolio and efforts to bring our pipeline of cancer medicines to patients around the world,” Jacob Van Naarden, SVP and CEO Lilly’s Loxo unit, said in a news release.
Fry is heading into retirement after more than 35 years at Eli Lilly, where he started as a systems analyst in Indiana back in 1987, according to his LinkedIn profile. Fry’s positions have spanned the globe, including HR director in the UK and general manager in Australia and New Zealand.
“Steve has left a positive and indelible imprint on the people, culture and performance of our company,” CEO David Ricks said in a news release. “Serving as our CHRO over the past 11 years, Steve has played a key role in leading us through the challenges we faced in those early years, modernizing so many dimensions of our HR function—including diversity, equity and inclusion—and leading the company’s efforts to become a premier employer around the world.”
That leaves Dozier with some big shoes to fill, though Ricks is confident he’s up for the task. Dozier has been with Lilly for nearly 25 years, hopping from roles such as chief marketing officer for Japan to VP of global ethics and compliance before settling in as Loxo CCO.
“Eric is the right leader to drive our people strategy and diversity, equity, and inclusion agenda as Lilly enters a new and exciting chapter of growth,” Ricks said.